+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dermal Mycosis Drug"

From
Dermal Mycosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Dermal Mycosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Dermal Mycosis - Pipeline Insight, 2024 - Product Thumbnail Image

Dermal Mycosis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Dermal mycosis is a type of fungal infection that affects the skin, hair, and nails. It is caused by a variety of fungi, including dermatophytes, yeasts, and molds. Treatment for dermal mycosis typically involves the use of antifungal drugs. These drugs can be administered topically, orally, or intravenously, depending on the severity of the infection. Common antifungal drugs used to treat dermal mycosis include terbinafine, itraconazole, fluconazole, and ketoconazole. The dermal mycosis drug market is a subset of the larger dermatological drugs market. It is composed of a variety of antifungal drugs used to treat dermal mycosis. These drugs are used to treat a wide range of fungal infections, including athlete's foot, jock itch, ringworm, and yeast infections. Some companies in the dermal mycosis drug market include Pfizer, Novartis, Merck, Johnson & Johnson, and GlaxoSmithKline. Show Less Read more